Latest Payments News

Paladin Energy reported a $18.4 million operating cash outflow in Q2 2025 but maintains a strong liquidity position with $89 million in cash and $139 million in total available funding.

Ampol Limited reports a solid first half of 2025 with earnings growth in Convenience Retail and New Zealand segments, while refinery margins show signs of recovery in the second quarter.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.

WAM Global Limited has updated its special fully franked dividend and clarified the Dividend Reinvestment Plan price for the six months ending December 2024, offering investors a clear view on income and reinvestment options.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

Bod Science reports a solid net cash inflow of $858,000 in Q4 FY2025, driven by R&D incentives and Biortica funding, while awaiting shareholder approval to complete a key acquisition.

Bod Science Limited reports a positive cash flow quarter driven by customer receipts, an R&D tax incentive, and proceeds from intellectual property sales, while navigating its Deed of Company Arrangement.

Southern Hemisphere Mining has secured a $13 million farm-in deal with FMR Resources to drill its highly prospective Curiosity copper-gold target in Chile, while also expanding its footprint with new exploration licenses in Western Australia.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

Dollarama Inc. has officially acquired The Reject Shop, paying shareholders $5.91 per share and triggering the retailer's imminent delisting from the ASX.

Alternative Investment Trust (ASX, AIQ) announces a special unfranked distribution of AUD 0.04647 per unit, representing a full return of capital payable in early August.